MOYOM Biotech Secures Financing to Propel Global Growth in Aesthetic Innovations

MOYOM Biotech Secures Vital Financing for Global Growth

In a significant step towards expanding its international footprint, MOYOM Biotech has successfully completed a financing round led by the Cathay Consumer Co-Creation Fund, part of Cathay Capital. This investment indicates a pivotal moment in MOYOM's strategy to revolutionize the field of regenerative aesthetics.

Founded in 2018 and headquartered in Shanghai, MOYOM Biotech specializes in developing advanced biomaterials for aesthetic applications, focusing primarily on regenerative techniques. The latest financing round aims to bolster MOYOM’s growth trajectory, providing essential resources for expanding its product offerings and enhancing its global outreach.

Cathay Capital's partnership, alongside L'Oréal and the Shanghai Jing'an District Government, underscores a commitment to fostering innovation within beauty, health, and skin science. This strategic collaboration not only facilitates MOYOM’s access to capital but also connects the company with a global network of industry leaders in consumer technology, healthcare, and biotechnology across various sectors.

The infusion of capital will enable MOYOM to accelerate its clinical translation efforts, pursue international regulatory approvals, and facilitate market entry into promising regions outside of China. The core of its innovation lies in its flagship product, Aphranel®, which is celebrated for its regenerative properties. Aphranel® is a calcium hydroxylapatite (CaHA) biostructure that provides immediate support while promoting natural regenerative processes. This unique product has already seen commercial success, with a presence established in over 700 aesthetic clinics throughout China since its launch in May 2025.

MOYOM’s proprietary technology encompasses two key innovations: ACD-MT®, featuring raspberry-shaped through-hole CaHA microspheres, and PCD-ETT®, which is a physically cross-linked CMC gel technology. These advancements ensure high performance, effective regenerative interaction, and gradual biodegradation, making them ideal for aesthetic applications.

With its recent regulatory approvals — including Class III medical device registration from China’s National Medical Products Administration in February 2025 and compliance with the European Union Medical Device Regulation achieved in May 2026 — MOYOM is positioned to broaden its influence in the international market.

As part of its growth strategy, MOYOM is focused not only on expanding its market presence but also on nurturing the continued development of next-generation biomaterials designed for regenerative medicine. The company is poised to set new standards in the medical aesthetics industry by leveraging innovative technologies and strong partnerships, facilitated by the investment from Cathay Capital.

This new phase represents not just an expansion of MOYOM’s product offerings, but a commitment to advancing the field of regenerative aesthetics globally. As the company seeks to establish Aphranel® as a leading science-driven brand worldwide, its journey highlights the potential of combining technology and health innovation.

Through these endeavors, MOYOM aims to redefine the standards of beauty and aesthetics while ensuring effective and safe products for consumers. Investors and industry stakeholders will be closely monitoring MOYOM’s next steps as it transitions into a broader global player in the regenerative aesthetics landscape.